Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | LATS1 | O95835 | 2/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.32 |
| ▸ | JUN | P05412 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.31 |
| ▸ | RELA | Q04206 | 2/20 | 0.31 |
| ▸ | BCL6 | P41182 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | XPO1 | O14980 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 2/20 | 0.30 |
| ▸ | BCR | P11274 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20390049 | 0.86 | MEN1 (0.37) | MEN1KMT2ASTK17BSTK17AMAPK8 | |
| SCHEMBL29474436 | 0.85 | STK17B (0.54) | MEN1KMT2ASTK17BSTK17ALATS1 | |
| SCHEMBL2722686 | 0.85 | STK17B (0.54) | MEN1KMT2ASTK17BSTK17ALATS1 | |
| SCHEMBL13649031 | 0.80 | MEN1 (0.44) | MEN1KMT2ASTK17BSTK17AMAPK8 | |
| SCHEMBL21967073 | 0.76 | MEN1 (0.37) | MEN1KMT2ASTK17BSTK17ANFKB1 | |
| SCHEMBL21388313 | 0.75 | MEN1 (0.38) | MEN1KMT2ASTK17BSTK17A | |
| SCHEMBL17595892 | 0.75 | STK17A (0.41) | MEN1KMT2ASTK17BSTK17ABTK | |
| SCHEMBL12984990 | 0.75 | MEN1 (0.42) | MEN1KMT2ASTK17BSTK17ALATS1 | |
| SCHEMBL25956733 | 0.75 | MEN1 (0.36) | MEN1KMT2ASTK17BSTK17A | |
| SCHEMBL12985024 | 0.75 | KMT2A (0.46) | MEN1KMT2ASTK17BSTK17ALATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | GI Therapeutics, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | MEN1 2275/4885KMT2A 276/4885STK17B 149/4885 |
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | MEN1 3666/4885KMT2A 513/4885STK17B 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.